All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lymphoma & CLL content recommended for you
Voxtalisib shows promising efficacy in R/R FL but not for other iNHL and CLL
A phase II non-randomized, open-label trial (NCT01403636) assessed the safety and efficacy of voxtalisib (XL765/SAR245409) in patients with specific lymphoma subtypes or leukemia. Voxtalisib is a reversible inhibitor of phosphoinositide-3 kinase (PI3K) and a weak inhibitor of the mammalian target of rapamycin (mTOR). The study by Jennifer Brown, medical oncologist at the Dana-Farber Cancer Institute, Boston, was published by The Lancet Haematology online on 14 March 2018.
Study Overview
- Patients were enrolled from 30 oncology clinics in USA, Europe and Australia
- Total number of patients (N = 167) enrolled in the study were diagnosed with relapsed or refractory (R/R); mantle cell lymphoma (MCL) n = 42, follicular lymphoma (FL) n = 47, diffuse large B-cell lymphoma (DLBCL) n = 42 and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) n = 36
- Patients received 50 mg oral voxtalisib twice daily in 28-day continuous cycles until disease progression or unacceptable toxicity
- The primary endpoint of the study was overall response rate (ORR) for each of the disease subtypes. Secondary endpoints included progression-free survival (PFS), duration of response (DOR) and safety
Key Findings
- Median follow-up for all patients = 16.4 weeks
- ORR for each subtype:
- MCL = 11.9% (95% CI, 4.0–25.6%)
- Complete response (CR) = 7.1% and partial response (PR) = 4.8%
- FL = 41.3% (95% CI, 27.0–56.8%)
- CR = 10.9% and PR = 30.4%
- DLBCL = 4.9% (95% CI, 0.6–16.5%)
- CR = 0% and PR = 4.9%
- CLL/SLL = 11.4% (95% CI, 3.2–26.7%)
- CR = 0% and PR = 11.4%
- Median PFS for each subtype:
- MCL = 8.9 weeks (95% CI, 7.86–12.86)
- FL = 58.0 weeks (95% CI, 26.00–not calculated)
- DLBCL = 7.1 weeks (95% CI, 5.14–8.14)
- CLL/SLL = 24.1 weeks (95% CI, 16.57–31.57
- MCL = 11.9% (95% CI, 4.0–25.6%)
Safety
- Most common adverse events grade ≥3:
- Anemia n = 21 (13%), pneumonia n = 15 (9%), fatigue n = 10 (6%) and diarrhea n = 5 (3%)
- 53 patient deaths were reported (32%), 43 deaths were due to disease progression and 8 due to adverse events considered unrelated to the study
From the results, voxtalisib demonstrated some promising efficacy in FL but not in the other lymphoma subtypes or CLL. The authors noted that voxtalisib had an acceptable safety profile and that it might therefore warrant further its study for the FL subtype.
References